electroCore (NASDAQ: ECOR) is one of 47 public companies in the “Electromedical equipment” industry, but how does it contrast to its peers? We will compare electroCore to similar companies based on the strength of its dividends, institutional ownership, profitability, analyst recommendations, risk, valuation and earnings.
Valuation and Earnings
This table compares electroCore and its peers gross revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|electroCore Competitors||$1.19 billion||$88.57 million||16.28|
This table compares electroCore and its peers’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Institutional & Insider Ownership
14.1% of electroCore shares are owned by institutional investors. Comparatively, 47.7% of shares of all “Electromedical equipment” companies are owned by institutional investors. 15.5% of shares of all “Electromedical equipment” companies are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
This is a summary of recent recommendations and price targets for electroCore and its peers, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
electroCore presently has a consensus target price of $20.25, suggesting a potential upside of 575.00%. As a group, “Electromedical equipment” companies have a potential upside of 24.50%. Given electroCore’s stronger consensus rating and higher probable upside, equities analysts clearly believe electroCore is more favorable than its peers.
electroCore peers beat electroCore on 7 of the 12 factors compared.
electroCore, Inc., a bioelectronic medicine company, engages in developing a range of patient-administered non-invasive vagus nerve (VNS) stimulation therapies for the treatment of various conditions in neurology, rheumatology, and other fields. The company is developing gammaCore, a prescription-only non-invasive VNS therapy for the acute treatment of pain associated with migraine and episodic cluster headache in adults. Its lead product is gammaCore Sapphire, which is a handheld delivery system for multi-year use prescribed on a monthly basis. The company was founded in 2005 and is headquartered in Basking Ridge, New Jersey.
Receive News & Ratings for electroCore Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for electroCore and related companies with MarketBeat.com's FREE daily email newsletter.